GLSI (Greenwich LifeSciences) Moat Score: 4/10 (As of Jul. 02, 2026)


GLSI Greenwich LifeSciences Inc GLSI
33 GF Score
Price $22.00
! 1 Warning Sign
View Full Analysis

What is Greenwich LifeSciences Moat Score?

Greenwich LifeSciences GLSI -7.17% 33 Moat Score is 4 as of Jul. 02, 2026. GuruFocus rates GLSI with a GF Score™ of 33/100. The stock has 1 warning sign investors should review. Among 1,400 Biotechnology companies, Greenwich LifeSciences ranks better than 88.79% on this metric.

Greenwich LifeSciences has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Greenwich LifeSciences has Narrow Moat: Greenwich LifeSciences Inc has a modest moat due to its focus on innovative cancer therapies and potential intellectual property. However, it remains in early stages with limited market impact and competitive pressures.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Greenwich LifeSciences might have Narrow Moat - Discernible but modest moat.

Greenwich LifeSciences  (NAS:GLSI) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Greenwich LifeSciences Moat Score Related Terms

GLSI vs SABS, SRZN, ZNTL: Moat Score Comparison

For the Biotechnology subindustry, Greenwich LifeSciences's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Greenwich LifeSciences Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Greenwich LifeSciences's Moat Score distribution charts can be found below:

* The bar in red indicates where Greenwich LifeSciences's Moat Score falls into.


GLSI
33GF Score
Greenwich LifeSciences Inc GLSI
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Greenwich LifeSciences (GLSI) has a Moat Score of 4 as of Jul. 02, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Greenwich LifeSciences ranks #157 out of 1400 companies in the Biotechnology industry, placing it in the top 11.2%.
Is Greenwich LifeSciences' Moat Score too high?
Greenwich LifeSciences' current Moat Score is 4. The Biotechnology industry median Moat Score is 2.00. Greenwich LifeSciences' value of 4 is 100% above this industry median. Based on the distribution chart, Greenwich LifeSciences ranks #157 out of 1400 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Greenwich LifeSciences has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Greenwich LifeSciences' Moat Score compare to SABS and SRZN?
According to the Biotechnology industry distribution chart, Greenwich LifeSciences ranks #157 out of 1400 companies for Moat Score. This places Greenwich LifeSciences in the top 11% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Greenwich LifeSciences' value of 4 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,400 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Greenwich LifeSciences's current Moat Score of 4 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Greenwich LifeSciences's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Greenwich LifeSciences stock overvalued right now?
Greenwich LifeSciences (GLSI) has a current Moat Score of 4. The current Moat Score is 4 and 100% above the Biotechnology industry median of 2.00. Greenwich LifeSciences' overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Greenwich LifeSciences (GLSI), the current Moat Score is 4 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Greenwich LifeSciences Business Description

Address 3992 Bluebonnet Drive, Building 14, Stafford, TX, USA, 77477
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.
33GF Score

Get the complete analysis for GLSI

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$22.00
Price